undamentalytics Newsletter
Sign in

Cardiff Oncology, Inc. (CRDF) stock

Add to watchlist

Add holding +

NASDAQ: CRDF Nasdaq Biotechnology Next results ~November 12, 2026

E Fundamentals grade

Cardiff Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.4

Growth cash-flow model

Base case. Range ~$0.4–$0.4. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Cardiff Oncology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds55 adding, 56 cuttingOf 17 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cardiff Oncology files

Where Cardiff Oncology stands after its latest 10-Q

Cardiff Oncology has little or no product revenue yet; it used $41m of cash in the twelve months to June 2026. The diluted share count is up 15.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Cardiff Oncology, Inc.'s trailing-twelve-month revenue fell 7.0% year on year, with a free-cash-flow margin of -8042.1%. Where it lags: stock pay as % of revenue of 1028.5% ranks 171 of 179 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 2.4% while net income grew 21.5%: a 19pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 1630.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 7.0% over the last 12 months.
  • Loss-making. Operating margin is -8320.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -8042.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 1028.5% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 15.8% in a year.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.14 against an average estimate of -$0.16: beat by 12.5%
Revenue
$0m, down 14.0% on a year earlier
Share reaction
-3.9% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.13

Cardiff Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.9%
  • 1 week-2.7%
  • 1 month-23.6%
  • This year-70.1%
  • 1 year-63.0%
  • 5 years-85.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$508,000
Operating margin
-8320.1%
Net margin
-7884.1%
EPS (TTM, diluted)
$-0.59

Growth

Revenue growth
−7.0%
Change in growth rate
+3.8 pts
Share count change
+15.8%

Cash

Free cash flow (TTM)
-$40.9M
FCF margin
-8042.1%
Stock pay % of revenue
1028.5%

Earnings

Last results
August 11, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Shareholder vote
  3. Agreement
  4. Results
  5. Agreement
  6. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cardiff Oncology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Cardiff Oncology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.22 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.4 ~$0.4–$0.4 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.0 ~$0.0–$0.1 Left out: out of range vs price (0.01x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.4 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cardiff Oncology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$388.80$151.20$22.32$3.18$1.24$17.99$6.01$1.40$1.48$4.34$2.81$0.84
Market value$51.4bn$22.9bn$54m$7m$7m$376m$235m$61m$66m$207m$188m$57m
+ Net debt (− = net cash)−$51m$3m−$6m−$11m−$10m−$131m−$12m−$16m−$22m−$51m−$17m−$9m
Enterprise value$51.4bn$22.9bn$48m−$4m−$3m$245m$223m$45m$44m$155m$170m$48m
Multiples
Price / sales n/mn/m106.4x19.6x30.3xn/mn/m158.1x135.5xn/mn/m112.1x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

5 /100

Weak moat

How hard Cardiff Oncology's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -64.6% of total assets over 10 years.

  • Pricing power 0 / 20

    Gross margin has been a median -101.0%, moving by 158.5 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -7515.7%; its worst year was -10350.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -6611.8% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 499.3% over five years; stock-based pay has been a median 883.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (10 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $86430 and EPS of −$0.13 (range −$0.14 to −$0.12) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.56 +19% $295140 −50%
Next −$0.54 +5% $320830 +9%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −18.1% on 90 days ago. In the last 30 days, 4 analysts raised Cardiff Oncology, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Cardiff Oncology, Inc., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.69 Current fiscal year, 60 days ago: −$0.69 Current fiscal year, 30 days ago: −$0.55 Current fiscal year, 7 days ago: −$0.56 Current fiscal year, Now: −$0.56 −$0.56 Next fiscal year, 90 days ago: −$0.81 Next fiscal year, 60 days ago: −$0.81 Next fiscal year, 30 days ago: −$0.63 Next fiscal year, 7 days ago: −$0.60 Next fiscal year, Now: −$0.54 −$0.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.69−$0.81
60 days ago −$0.69−$0.81
30 days ago −$0.55−$0.63
7 days ago −$0.56−$0.60
Now −$0.56−$0.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.16 −$0.14 +12.5%
Mar 2026 −$0.12 −$0.18 −45.2%
Dec 2025 −$0.20 −$0.11 +44.1%
Sept 2025 −$0.21 −$0.17 +18.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 11, 2026

No numeric guidance in Cardiff Oncology, Inc.'s latest earnings release (filed August 11, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy350%
Hold350%
Sell00%

Monthly trend

  1. Oct 20261236
  2. Sep 20261146

Counts of recommendations published by analysts covering Cardiff Oncology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.9%
of tradable shares
Days to cover
17.7
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
22%
of shares
Held by insiders
6.2%
of shares
Employees
30
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −64.3%

$2.35 on October 31, 2025 to $0.84

ThenNowEffect
Revenue (last 12 months) $546000 $508000 −7.0%
P/S multiple n/m 112.1x −55.5%
Share count 59m 68m −13.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CRDF−67%−77%+6%+193%−35%−70%
Industry peers (median)−35%−56%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CRDF25%42%50%58%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CRDF−74%−84%−56%−65%−59%−75%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 25, 2015 to March 18, 2020. Getting back needed a 67814% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.80 – $3.21
From 52-week high
−73.8%
vs 50-day average
−22.2%
vs 200-day average
−41.2%
Volatility (1 year)
87%
Beta vs S&P 500
1.77

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±14.2%
After a week
4 up, 8 down
typical move ±20.7%
After a month
6 up, 6 down
typical move ±40.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −3.9% −0.1% −13.6% +17.5%
May 14, 2026 −1.2% −0.4% +5.9% −16.0%
November 6, 2025 −2.2% −1.0% −4.0% +4.5%
July 29, 2025 −33.2% −0.4% −31.1% −41.8%
May 8, 2025 +6.8% +0.6% +10.4% +55.0%
February 27, 2025 −4.9% −0.1% −13.0% −26.2%
November 7, 2024 −19.2% +1.2% −25.5% −36.0%
August 8, 2024 +11.2% +2.8% +11.7% +7.9%
May 2, 2024 −16.8% +2.2% −20.1% −25.1%
February 29, 2024 +59.9% +1.3% +92.9% +214.8%
November 2, 2023 +5.7% +2.8% −6.7% +22.9%
August 9, 2023 −5.0% −0.6% −13.3% −15.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cardiff Oncology, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cardiff Oncology, Inc.
$400K $500K $600K $700K FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $460K Revenue (TTM), FY23 Q4: $488K Revenue (TTM), FY24 Q1: $610K Revenue (TTM), FY24 Q2: $665K Revenue (TTM), FY24 Q3: $689K Revenue (TTM), FY24 Q4: $684K Revenue (TTM), FY25 Q1: $588K Revenue (TTM), FY25 Q2: $546K Revenue (TTM), FY25 Q3: $501K Revenue (TTM), FY25 Q4: $593K Revenue (TTM), FY26 Q1: $525K Revenue (TTM), FY26 Q2: $508K $508K

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $460K
FY23 Q4 $488K
FY24 Q1 $610K
FY24 Q2 $665K
FY24 Q3 $689K
FY24 Q4 $684K
FY25 Q1 $588K
FY25 Q2 $546K
FY25 Q3 $501K
FY25 Q4 $593K
FY26 Q1 $525K
FY26 Q2 $508K
Revenue growth, TTM YoY Cardiff Oncology, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 17.6% Revenue growth, TTM YoY, FY23 Q4: 26.4% Revenue growth, TTM YoY, FY24 Q1: 54.4% Revenue growth, TTM YoY, FY24 Q2: 61.4% Revenue growth, TTM YoY, FY24 Q3: 49.8% Revenue growth, TTM YoY, FY24 Q4: 40.2% Revenue growth, TTM YoY, FY25 Q1: -3.6% Revenue growth, TTM YoY, FY25 Q2: -17.9% Revenue growth, TTM YoY, FY25 Q3: -27.3% Revenue growth, TTM YoY, FY25 Q4: -13.3% Revenue growth, TTM YoY, FY26 Q1: -10.7% Revenue growth, TTM YoY, FY26 Q2: -7.0% -7.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 17.6%
FY23 Q4 26.4%
FY24 Q1 54.4%
FY24 Q2 61.4%
FY24 Q3 49.8%
FY24 Q4 40.2%
FY25 Q1 -3.6%
FY25 Q2 -17.9%
FY25 Q3 -27.3%
FY25 Q4 -13.3%
FY26 Q1 -10.7%
FY26 Q2 -7.0%
Operating margin (TTM) Cardiff Oncology, Inc.
-15000% -10000% -5000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -9667.8% Operating margin (TTM), FY23 Q4: -9305.7% Operating margin (TTM), FY24 Q1: -7261.1% Operating margin (TTM), FY24 Q2: -6711.3% Operating margin (TTM), FY24 Q3: -6736.0% Operating margin (TTM), FY24 Q4: -7112.7% Operating margin (TTM), FY25 Q1: -8860.5% Operating margin (TTM), FY25 Q2: -9950.9% Operating margin (TTM), FY25 Q3: -10719.6% Operating margin (TTM), FY25 Q4: -8256.3% Operating margin (TTM), FY26 Q1: -9033.9% Operating margin (TTM), FY26 Q2: -8320.1% -8320.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -9667.8%
FY23 Q4 -9305.7%
FY24 Q1 -7261.1%
FY24 Q2 -6711.3%
FY24 Q3 -6736.0%
FY24 Q4 -7112.7%
FY25 Q1 -8860.5%
FY25 Q2 -9950.9%
FY25 Q3 -10719.6%
FY25 Q4 -8256.3%
FY26 Q1 -9033.9%
FY26 Q2 -8320.1%
FCF margin (TTM) Cardiff Oncology, Inc.
-10000% -5000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -7345.0% FCF margin (TTM), FY23 Q4: -6448.6% FCF margin (TTM), FY24 Q1: -5020.0% FCF margin (TTM), FY24 Q2: -4882.6% FCF margin (TTM), FY24 Q3: -5029.5% FCF margin (TTM), FY24 Q4: -5522.4% FCF margin (TTM), FY25 Q1: -7269.9% FCF margin (TTM), FY25 Q2: -7663.9% FCF margin (TTM), FY25 Q3: -8427.7% FCF margin (TTM), FY25 Q4: -6395.1% FCF margin (TTM), FY26 Q1: -7127.0% FCF margin (TTM), FY26 Q2: -8042.1% -8042.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -7345.0%
FY23 Q4 -6448.6%
FY24 Q1 -5020.0%
FY24 Q2 -4882.6%
FY24 Q3 -5029.5%
FY24 Q4 -5522.4%
FY25 Q1 -7269.9%
FY25 Q2 -7663.9%
FY25 Q3 -8427.7%
FY25 Q4 -6395.1%
FY26 Q1 -7127.0%
FY26 Q2 -8042.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1
Gross profit — — — 0 −0 −1 −1 −0 0 — — — — — — —
EBITDA −3 −5 −11 −15 −25 −39 −24 −16 −16 −19 −28 −40 −45 −48 −49 −42
Operating income −3 −5 −11 −15 −25 −40 −26 −17 −17 −19 −29 −40 −45 −49 −49 −42
Net income −2 −12 −12 −14 −27 −39 −25 −16 −16 −19 −28 −39 −41 −45 −46 −40
Diluted EPS −$0.05 −$0.18 −$0.14 −$0.18 −$0.24 −$0.27 −$10.35 −$8.26 −$2.80 −$1.08 −$0.73 −$0.89 −$0.93 −$0.95 −$0.69 −$0.59
Growth (year on year)
Revenue — +74.8% −42.4% +8.1% +11.6% +21.8% +32.6% −25.1% −35.3% +49.6% −1.9% +7.5% +26.4% +40.0% −13.2% −7.0%
Margins
Gross margin — — — 94.5% −101.1% −354.1% −258.4% −57.9% 100.0% — — — — — — —
EBITDA margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Net margin −868.9% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Free-cash-flow margin −749.7% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Cash flow
Cash from operations −2 −5 −7 −13 −22 −31 −23 −13 −13 −16 −23 −34 −31 −38 −38 −41
Capital spending 0 0 1 0 2 1 0 0 0 0 0 1 1 0 0 0
Free cash flow −2 −5 −8 −13 −24 −32 −23 −13 −13 −17 −23 −35 −31 −38 −38 −41
Stock-based pay 0 1 2 2 4 8 4 2 1 2 3 4 5 5 6 5
Free cash flow after stock pay −2 −6 −10 −15 −28 −39 −27 −15 −14 −18 −26 −39 −36 −43 −44 −46
Balance sheet
Cash 1 11 26 67 67 14 8 11 10 131 12 16 22 51 17 9
Total debt 0 0 1 15 17 17 3 — 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −1 −11 −25 −53 −51 3 −6 −11 −10 −131 −12 −16 −22 −51 −17 −9
Diluted shares 49m 65m 85m 95m 132m 151m 2m 2m 6m 21m 39m 44m 45m 48m 67m 68m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $37m
Short-term assets $36mLonger-term assets $2m
What it owes, and who funded it · $37m
Short-term liabilities $11mLonger-term liabilities $0mShareholders' equity $27m
  • Short-term assets cover short-term liabilities $36m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $36m short-term assets against $0 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cardiff Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+15.8%
year over year
R&D spending
5108.7%
of revenue
Sales & admin spending
3311.4%
of revenue
Days sales outstanding
136 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CRDF CRVO MNOV STTK LGVN CLNN Median
Revenue, last 12 months $508000 $331295 $920481 $1m $1m $197000 $56m
Revenue growth, last 12 months −7.0% −95.7% 875.7% −66.6% −42.7% −31.1% 12.6%
Revenue growth, 3-year average 7.2% −52.7% — 5.2% 10.4% −36.9% 13.7%
Revenue growth, latest quarter −14.0% −100.0% 240.6% −66.6% −9.2% 233.3% 10.2%
Gross margin 100.0% 100.0% 100.0% — 69.8% 70.1% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −189.4%
Operating margin, 3-year average <−999% <−999% −905.8% <−999% <−999% <−999% −363.5%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −169.8%
Cash from operations / revenue <−999% <−999% −989.7% <−999% <−999% <−999% −168.0%
Free-cash-flow margin <−999% — −991.2% <−999% <−999% <−999% −162.4%
Free-cash-flow margin, 3-year average <−999% — <−999% <−999% <−999% <−999% −310.0%
Stock pay / revenue >999% 393.0% 100.3% 853.2% 132.8% >999% 20.0%
Change in share count 15.8% 8.4% 0.2% 15.3% — 35.4% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -7.0% 12.6% 114 of 172
Change in growth rate Growth +3.8pp -0.1pp 59 of 172
Operating margin Profitability -8320.1% -189.4% 165 of 175
Net margin Profitability -7884.1% -157.3% 169 of 180
Free-cash-flow margin Cash generation -8042.1% -145.4% 167 of 176
Stock pay as % of revenue Cash generation 1028.5% 19.2% 171 of 179
Change in share count Balance sheet 15.8% 7.9% 107 of 156
Days sales outstanding Balance sheet 136 days 75 days 81 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$24.3M
Institutions reporting
104
Shares held vs prior quarter
▼ 23.6%
Positions opened / closed
20 / 30

Top buyers and sellers, Q2 2026: 55 institutions bought and 56 sold ; the biggest buyer was Jane Street Group, LLC (+568K shares) and the biggest seller Blackrock, Inc (−3.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Laurion Capital Management LP $4M 3.1M 16.6% ▲ 17.1%
Vanguard Capital Management LLC $3.8M 2.9M 15.5% ▲ 1.4%
Pfizer Inc $3M 2.4M 12.4% 0.0%
Franklin Resources Inc $1.6M 1.2M 6.4% 0.0%
Blackrock, Inc. $1.3M 973K 5.2% ▼ 75.6%
Blair William & Co $1.2M 913K 4.9% ▼ 1.1%
Geode Capital Management, LLC $1.1M 820K 4.4% ▼ 48.7%
UBS Group AG $830,309 639K 3.4% ▲ 59.4%
Jane Street Group, LLC $790,270 608K 3.3% ▲ 1415.8%
Vanguard Fiduciary Trust Co $533,783 411K 2.2% ▼ 8.0%
AQR Capital Management LLC $450,260 346K 1.9% ▲ 423.5%
State Street Corp $430,814 331K 1.8% ▼ 72.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cardiff Oncology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.1M 4 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.1M net buying
Insider Date Trade Shares Price Value
Mohindru Mani Chief Executive Officer July 14, 2026 Buy 34,364 $1.46 $50,171
Pace Gary W Director July 14, 2026 Buy 687,285 $1.46 $1M
Pace Gary W Director June 18, 2026 Buy 30,000 $1.22 $36,600
Mohindru Mani Chief Executive Officer June 18, 2026 Buy 24,703 $1.21 $29,891

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 14, 2026
  • November 6, 2025
  • July 29, 2025
  • May 8, 2025
  • February 27, 2025

Recent SEC filings

Data status

When each part of this page on Cardiff Oncology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cardiff Oncology, Inc. in brief

What does Cardiff Oncology, Inc. do?
Cardiff Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cardiff Oncology, Inc.'s stock ticker?
Cardiff Oncology, Inc. trades under the ticker CRDF on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cardiff Oncology, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cardiff Oncology, Inc. reported revenue of $508,000, 7.0% lower than a year earlier, according to its SEC filings.
What is Cardiff Oncology, Inc.'s free cash flow?
Cardiff Oncology, Inc.'s free-cash-flow margin is -8042.1% of revenue over the trailing twelve months, ranking 167 of the 176 biotechnology companies we cover.
Who are Cardiff Oncology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Laurion Capital Management LP, Vanguard Capital Management LLC and Pfizer Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cardiff Oncology, Inc.'s market cap?
On November 2, 2026, Cardiff Oncology, Inc.'s market capitalisation was about $56.9M and net debt of -$9.2M. Market figures come from third-party market data and may be delayed.
Who are Cardiff Oncology, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Cardiff Oncology, Inc. are Cervomed Inc., Medicinova Inc, Shattuck Labs, Inc., Longeveron Inc. and Clene Inc. The side-by-side comparison below sets their revenue, margins and growth against Cardiff Oncology, Inc.'s.
Are insiders buying or selling Cardiff Oncology, Inc. stock?
Over the last 12 months, Cardiff Oncology, Inc.'s directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Cardiff Oncology, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cardiff Oncology, Inc. announces its own schedule.